Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to keep opioid overdose survivors on track to recovery

NCT ID NCT03895827

Disease control Sponsor: Chestnut Health Systems Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a program called RIMO that helps people who recently survived an opioid overdose get into medication-assisted treatment (MAT). The program uses motivational interviewing and support to encourage people to start and stay on MAT. Researchers worked with first responders in Chicago to identify and enroll 251 participants. The goal is to see if this approach leads to faster treatment initiation and longer recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Recovery Initiation and Management after Overdose (RIMO) - a behavioral program using motivational interviewing and linkage assistance
What this could lead to
If it works, this program could help more people start and stay on medication-assisted treatment after an overdose, reducing the risk of future overdoses.
What could go wrong
This is a behavioral intervention, not a drug, so results depend on participant engagement. The study is completed but relatively small (251 people) and limited to Chicago, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

251 people

The number who actually took part.

Started

Apr 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * experienced an opioid overdose reversed with naloxone administered by first responders on a participating team within the past week * not in treatment during the past 30 days * screen positive for an OUD Exclusion Criteria: * under age 18 * unable to speak and understand English * not residing in Chicago * cognitively unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence Opiate Overdose

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use disorder

Contacts and locations

Locations

  • Chestnut Health Systems

    Chicago, Illinois, 60610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.